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Classical therapy of heart failure is based on treatment of its pre-disposing/triggering factors and of the neuro-
humoral activation secondary to the deterioration of cardiac function. A new view is emerging that proposes the
direct intervention on the pathological structural remodeling of the myocardium as part of heart failure therapy.
In fact, in conditions of chronic injury, the cardiomyocytic and the noncardiomyocytic components of the myocar-
dium undergo a series of structural lesions (i.e., cardiomyocyte growth and death, inflammation, alterations of
collagen matrix, and microvascular rarefaction) that are governed by a complex interplay of mechanisms. Our
increasing knowledge of the role of these mechanisms in remodeling enables us not only to better understand
how our more successful therapies work but also to explore novel therapies for the future. In this paper, we will
examine recent insights from experimental and pilot clinical studies that have provided new targets for interven-
tions to prevent or reverse inflammation, alterations of collagen matrix, and cardiomyocyte death. (J Am Coll
Cardiol 2011;58:1833–43) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.058The concept of cardiac remodeling was initially created to
describe the changes in the anatomy of the left ventricle
that occur after myocardial infarction. Today, myocardial
remodeling is used to describe a variety of changes in the
biophysiology of the cardiomyocyte, the volume and
composition of cardiomyocyte and noncardiomyocyte
compartments, and the geometry and architecture of the
left ventricular (LV) chamber that occur in response to
myocardial infarction, pressure or volume overload, car-
diomyopathic states, and exposure to infectious or car-
diotoxic agents (1). Myocardial remodeling results from
modifications that are not necessarily adaptive to the
initial insult, but pathologic and potentially self-
perpetuating in a progressive vicious circle (2). Myocar-
dial remodeling may result in alterations of cardiac
energetics, compromise of intramyocardial perfusion, de-
terioration of both diastolic and systolic function, and
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remodeling is a key determinant of the clinical course and
outcome of a number of cardiac diseases evolving with
chronic heart failure (HF) (Fig. 1).
HF has become a major clinical and public health
challenge. Since conventional strategies for the treatment of
HF are still largely based on targeting its causes and its
neurohumoral consequences, a broader perspective may be
useful for the development of novel medical therapies to
prevent or even reverse myocardial remodeling and reduce
the burden of HF. In this conceptual framework, gene
expression profiling (microarray) studies have identified
gene cluster expression profiles that may be involved in the
structural remodeling of the myocardium. Genes associated
with remodeling were largely those involved in cardiomyo-
cyte hypertrophy and death, inflammation, alterations of
collagen matrix, and microvascular rarefaction (3,4).
Since the antiremodeling effects of current pharmacolog-
ical (5) and device-based (6) measures to treat HF have
been recently reviewed, this article will focus on experi-
mental and clinical studies that have provided new
therapeutic targets. In addition, given that novel thera-
pies for cardiomyocytic hypertrophy (7) and microvascu-
lar rarefaction (8) have been addressed recently else-
where, the insights for new interventions on myocardial
inflammation, fibrosis, and cardiomyocyte death will be
considered in this article. This said, it is necessary to
remark that HF is a clinical syndrome that necessarily
reflects a diversity of patterns of structural myocardial
remodeling both in qualitative and quantitative terms
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Myocardial Remodeling October 25, 2011:1833–43(Table 1) (9 –11). As a conse-
quence, the impact of the different
therapeutic strategies here reviewed
on the components of myocardial
remodeling requires a critical and
cautious approach.
Inflammation
Upon activation of the innate im-
mune system by cardiac injury,
several inflammatory mediators are
released and inflammatory cells are
attracted to the myocardial site of
injury (12). All these humoral and
cellular factors have distinct func-
tions in the remodeling process.
For instance, cytokines such as in-
terleukin (IL)-1 and tumor ne-
crosis factor (TNF)- are involved
in cardiomyocyte apoptosis and
activation of matrix metalloproteinases (MMPs) that can
degrade the physiological collagen scaffold of the myocardium
(13,14) (Fig. 2). The resulting collagen fragments exert potent
pro-inflammatory actions, while MMPs can also process cy-
tokines and chemokines altering their biological activity (14).
Conversely, whereas neutrophils release oxidants and proteases
also involved in apoptosis and collagen degradation, mono-
cytes/macrophages stimulate fibroblast- and myofibroblast-
mediated synthesis and deposition of collagen fibers contrib-
uting to the development of myocardial fibrosis (15) (Fig. 2).
Abbreviations
and Acronyms
HF  heart failure
IGF  insulin-like growth
factor
IL  interleukin
LV  left ventricular
microRNA  micro-
ribonucleic acid
MMP  matrix
metalloproteinase
NF  nuclear factor
PCP  procollagen type I
carboxy-terminal proteinase
TGF  transforming growth
factor
TLR  toll-like receptor
TNF  tumor necrosis factor
Figure 1 Pathogenesis of Heart Failure
The lesions responsible for myocardial remodeling are critically involved in the det
clinical cardiac decompensation. *Neurohormonal mechanisms activated to maintAlthough several studies have shown raised levels of
inflammatory cytokines such as TNF-, IL-1, and IL-6 in
he circulation of patients with HF (16), the results of large
linical trials based on anticytokine therapy for patients with
F have been largely disappointing due to either neutral or
egative findings (17,18). In this regard, there are several
undamental issues to be dealt with. Is inflammation in HF
he same as in conditions such as cancer or rheumatoid
rthritis, in terms of cytokines and their dependent path-
ays activation, despite differences in the degree of inflam-
ation? And more importantly, does inflammation have the
ame impact among different HF etiologies and in the
ifferent stages of evolution? If inflammation pathways are
edundant in HF, theoretically it is not sensible to focus
ntervention on individual cytokines rather than on the
ytokine network. Therefore, much work is needed to clarify
he physiological role of both individual cytokines and
ytokine networks, in different stages of HF, due to different
tiologies, and compared with other known inflammatory
iseases.
Conversely, an improvement in the understanding of the
nderlying mechanisms involved in clinical responses to
nti-inflammatory agents is required. This is illustrated by
ata from a recent review of the potential beneficial mode of
ction of pentoxifylline, a putative TNF- inhibitor in HF
(19). In their review, the investigators showed that several
trials have reported improved clinical outcome after pen-
toxifylline treatment, but without a concordant effect on
TNF- modulation, suggesting that these beneficial effects
may not necessarily occur through TNF- inhibition, but
ion of left ventricular (LV) morphology and function that leads to
pumping capacity of the heart initially compromised by the triggering injury.eriorat
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October 25, 2011:1833–43 Myocardial Remodelingmay be mediated by other subtle effects on arterial vascula-
ture. Therefore, future basic and clinical research based on
anti–TNF- therapy should establish the best type of
urrently available antagonists (e.g., the fusion protein
tanercept, and the monoclonal antibodies infliximab, ada-
imumab, certolizumab, and golimumab), the optimal dos-
ge, which subgroups of chronic HF to treat, and the
utative molecular mechanisms involved in clinical changes
efore any firm conclusions regarding efficacy can be drawn.
Novel potential therapeutic options to reduce inflamma-
ion in chronic HF are emerging from pre-clinical discov-
ries. For instance, pentraxin 3, a molecule produced by
Heterogeneity of Myocardial Structural Remodeling in Different CarTable 1 Heterogeneity of Myocardial Structural Remodeling in
Fibrosis
Disease Inflammation Reactive Re
Hypertensive heart disease  
Ischemic heart disease / 
Dilated cardiomyopathy / 
Myocarditis  
Diabetic cardiomyopathy  
Aortic valve stenosis  
Semiquantitative score of the severity of the lesions:   low;   moderate;   high
contradictory. Elaborated with information reviewed in Graham et al. (9), Dorn (10), and Jiang an
Figure 2 Schematic of Pathways
Schematic representation of the pathways through which myocardial inflammation
characterize myocardial remodeling (i.e., apoptosis and fibrosis). IL  interleukin;onocytes, macrophages, and vascular and fibrogenic cells
n response to IL-1 and TNF- (20), seems to counteract
the detrimental effects of these cytokines and exert anti-
remodeling actions in the ischemic injured heart (21).
Moreover, TG100-115, a compound that inhibits the cat-
alytic domain of the enzyme PI3K/, a crucial component
f signal transduction controlling the recruitment of white
lood cells from the blood stream into tissues (22), has been
hown to exert cardiac protective effects in animal models of
schemia/reperfusion (23). Intervention on the downstream
annose-binding lectin complement-activating pathway,
hich has been recently reported to be increased in the left
Diseases at Heart Failure Stageent Cardiac Diseases at Heart Failure Stage
Collagen
Scaffold Cardiomyocyte Death
ve Disruption Apoptosis Necrosis Autophagy
 
   
   
 
  
 
theses indicate that the information about the presence of reparative fibrosis in myocarditis is
11).
cilitate the development of other lesions that
transforming growth factor; TNF  tumor necrosis factor.diacDiffer
parati


()
may fa
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Myocardial Remodeling October 25, 2011:1833–43ventricle of mice with experimentally-induced myocardial
infarction and continuous up-regulation of the IL-6 acti-
vated gp130/STAT3 signaling pathway (24), may represent
a novel therapeutic target to tackle inflammation after
cardiac injury. Although data from pre-clinical studies
suggest that inhibition of toll-like receptor 4 (TLR4) may
be a novel therapeutic strategy for myocardial remodeling
associated with ischemic HF (25), this may not be a
promising therapeutic avenue because TLR4 inhibition may
lead to a functional loss of the innate immune mechanisms,
and, thus, the global prognosis may not be improved.
Targeting the vicious inflammation-oxidative stress cycle
can be another approach to interfere with the remodeling
effects of inflammation. Recently, it has been proposed that
maintenance of an optimal balance between 2 of the major
cytokines that are demonstrably connected to oxidative
stress, the pro-inflammatory TNF- and the anti-
inflammatory IL-10, may be of crucial importance in
mitigating both inflammation and oxidative stress processes
leading to myocardial remodeling and HF (26) (Fig. 2). The
finding that patients with advanced HF exhibit a low
IL-10:TNF- ratio in blood (27) adds further support to
this notion. In this regard, it has been reported that
treatment with recombinant IL-10 inhibits TNF-–
dependent inflammation and oxidative stress, and attenuates
myocardial remodeling and LV dysfunction in a murine
model of HF (28).
Although the influence of inflammatory pathways on
cardiomyocyte survival is a matter of controversy, it offers a
window of therapeutic opportunity. Indeed, the nuclear
factor (NF)-B super family of transcription factors has
been implicated in the regulation of the life-death switch in
many cell types, including cardiomyocytes (29). Whereas it
has been shown that NF-B is cardioprotective during acute
hypoxia and reperfusion injury (30), prolonged activation of
NF-B appears to be detrimental and to promote HF by
eliciting signals that trigger chronic inflammation through
enhanced production of cytokines including TNF-, IL-1,
nd IL-6, leading to endoplasmic reticulum stress responses
nd cell death (31). Although the underlying mechanisms
hat account for the multifaceted and differential outcomes
f inflammation on cardiac cell fate are presently unknown,
t has been proposed that therapies designed to modulate
F-B activity in the heart temporally and spatially hold
promise for mitigating both inflammation and aberrant
cardiomyocyte death after injury (32).
In summary, as recently proposed by an expert group of
the Heart Failure Association of the European Society of
Cardiology (33), several requirements need to be accom-
plished by future studies in the field of anti-inflammatory
therapies for HF to establish their usefulness and safety
(33). In particular, a more careful and precise patient
selection for upcoming clinical trials of anti-inflammatory
agents in HF, as well as more fundamental pre-clinical
studies including better animal models are recommended. tAlterations of Collagen Matrix
Although fibrosis is commonly found in the setting of the
ischemic scar (i.e., reparative or replacement fibrosis), there
is increasing recognition of diffuse interstitial and perivas-
cular myocardial fibrosis (i.e., reactive fibrosis) occurring
either in regions remote to the infarct or as a separate entity
in a variety of conditions in the absence of infarct, including
hypertensive heart disease, diabetic cardiomyopathy, hyper-
trophic cardiomyopathy, and idiopathic dilated cardiomy-
opathy (34). Whereas reparative fibrosis may contribute to
preserve LV morphology and systolic function (i.e., prevent-
ing adverse geometric remodeling) (35), reactive fibrosis is
thought to contribute to the deterioration of LV function
(i.e., impairing the mechanical properties of the left ventri-
cle during diastole) and electrical activity (i.e., facilitating
arrhythmogenesis) (36). Because of space limitations, we
will focus our attention on pathologic myocardial fibrosis.
Given the dynamic nature of the myocardial collagen
network, fibrosis can be viewed as the result of the unbal-
ance between the enhanced synthesis of collagen types I and
III and unchanged or reduced collagen degradation (34).
In the clinical setting, some data with drugs used for
standard therapy of cardiac diseases support the notion that
myocardial fibrosis can be targeted with beneficial clinical
impact. In small clinical studies performed in hypertensive
patients with histologically proven myocardial fibrosis, it has
been shown that treatment with the angiotensin-converting
enzyme inhibitor lisinopril was able to reduce the extent of
myocardial fibrosis, and that this effect was associated with
improved LV diastolic dysfunction (37). Similarly, treat-
ment with the angiotensin-II receptor blocker losartan
diminished myocardial fibrosis, and this was accompanied
by a decrease in LV stiffness (38). Additionally, in hyper-
tensive patients with clinical HF, treatment with the loop
diuretic torasemide in addition to standard therapy, which
was able to reduce myocardial fibrosis, improved New York
Heart Association functional class in these patients (39).
Data from the RALES (Randomized Aldactone Evaluation
Study) and EPHESUS (Eplerenone Heart Failure Efficacy
and Survival Study) studies support a beneficial role for
mineralocorticoid receptor antagonists on extracellular ma-
trix turnover, as assessed by circulating biomarkers of
collagen metabolism, with a positive impact in post-infarct
remodeling and clinical outcome (reviewed in [40]).
The synthesis of fibrillar collagen is regulated by myofi-
broblasts (41). The origin of myofibroblasts is unclear but
may result from growth factor-mediated (e.g., transforming
growth factor [TGF]-, platelet-derived growth factor) and
hormone-mediated (e.g., endothelin-1, angiotensin II, al-
dosterone) differentiation of resident fibroblasts or recruit-
ment of microvascular pericytes or endothelial cells, as well
as from progenitor stem cells present in the circulation or in
the heart itself (41). For instance, it has been recently
reported that TGF- released by inflammatory cells induces
he transdifferentiation of fibroblasts to myofibroblasts and
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October 25, 2011:1833–43 Myocardial Remodelingthe subsequent synthesis and deposition of collagen in the
myocardium of patients with HF and preserved ejection
fraction (42). In this regard, compounds that act at the level
of the TGF- heteromeric receptor may be a useful ap-
roach to interfere with the fibrotic process. In fact, in an
xperimental rat model of myocardial infarction, treatment
ith a TGF- type I receptor inhibitor significantly reduced
TGF- activity, leading to the attenuation of myocardial
emodeling and LV dysfunction (43). Conversely, a syn-
hetic peptide from TGF- type III receptor (betaglycan)
has been shown to inhibit TGF-–dependent signaling
athway and collagen type I synthesis in cardiac fibroblasts,
s well as to prevent myocardial fibrosis in rats with
pontaneous hypertension (44).
Collagen types I and III are secreted by myofibroblasts as
rocollagen type I and III precursors having N-terminal and
-terminal propeptides that are cleaved to yield the triple
elical monomers (45) (Fig. 3). The enzyme procollagen
ype I carboxy-terminal proteinase (PCP) is a neutral,
alcium-dependent proteinase responsible for the cleavage
f the carboxy-terminal propeptide of procollagen type I
45) (Fig. 3). In addition, PCP stimulates extracellular
ctivation of the enzyme lysyl oxidase that controls the
ormation of covalent cross-links between collagen type I
olecules to form insoluble stiff collagen type I fibrils (45)
Fig. 3). Evidence from experimental and clinical studies
Figure 3 Schematic of Extracellular Steps
Schematic representation of the extracellular steps involved in the generation and
(leading to the formation of the myocardial collagen scaffold) and pathologic condhows that the excess of PCP and lysyl oxidase is associated
ith an increase in myocardial collagen type I synthesis,
ross-linking, and deposition observed in different cardiac
iseases (46). Of interest, recent findings show that these
lterations are associated with impaired diastolic function
nd reduced exercise tolerance in patients with HF and
reserved ejection fraction (47). In this regard, it has been
eported that, in contrast to the addition of furosemide, the
ddition of torasemide to standard HF therapy reduced the
xcess of PCP and lysyl oxidase, as well as the exaggerated
ross-linking and deposition of collagen fibers present in the
yocardium of patients with HF (48,49).
Other emerging possibilities to act therapeutically on myo-
ardial fibrosis involve micro-ribonucleic acids (microRNAs)
nd stem cells. Altered regulation (mostly up-regulation) of
number of specific microRNAs related to myocardial
brosis has been found in animal models of LV hypertrophy
nd failure, and in human end-stage HF (50). The first
uccessful antagomir treatment of myocardial fibrosis and
F in a murine pressure overload model using specific
iR-21 antagonists (51) paved the way for microRNA
anipulation as a novel treatment strategy to prevent and
reat LV fibrosis, hypertrophy, and failure. Conversely,
irect injection of human stem cells—in particular, mesen-
hymal stem cells—into ischemic rat myocardium decreased
brosis, and that resulted in the prevention of systolic and
ition of collagen type I fibers in normal conditions
leading to myocardial fibrosis). DNA  deoxyribonucleic acid.depos
itions (
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Myocardial Remodeling October 25, 2011:1833–43diastolic LV dysfunction without evidence of myocardial
regeneration (52). Additionally, stem cell transplantation
significantly attenuated the increase in cardiac expression of
collagen types I and III, and TGF- in the infarcted
myocardium (53). Because stem cells express a number of
molecules involved in the biogenesis of extracellular matrix
such as adrenomedullin, thymosin-, thymocollagenase,
MPs, serine proteases, and their inhibitors, it has been
uggested that transplanted stem cells can inhibit fibrosis
hrough paracrine actions (54). However, the understanding
f the underlying mechanisms, delivery, specificity, and potential
oxicity of such microRNAs and stem cells needs to be improved
o consider their future therapeutic applicability.
It is important to mention that there are clinical condi-
ions in which excessive degradation of the physiologic
ardiac collagen scaffold (i.e., endomysial and perimysial
ollagen) coexists with pathologic collagen deposition or
brosis. For instance, in post-myocardial infarction, activa-
ion of myocardial MMP-2 and MMP-9 has been docu-
ented and demonstrated to be involved in collagen scaffold
egradation, LV dilation, and compromise of cardiac sys-
olic function (55). In addition, an association between
yocardial MMP-1 up-regulation and reduction of colla-
en scaffold has been reported in hypertensive patients with
V dilation and systolic HF (56). Furthermore, adminis-
ration of glucocorticosteroids and nonsteroidal anti-
nflammatory drugs during the acute post-myocardial in-
arction period has been shown to result in increased
nfarct-associated MMP levels and activity, increased thin-
ing of the infarct zone, greater degrees of infarct expan-
ion, and LV dilation and dysfunction (57,58). In this
egard, although earlier proof-of-concept pre-clinical stud-
es of nonselective MMP inhibitors had yielded promising
esults in preventing post-myocardial remodeling, data from
he PREMIER (Prevention of Myocardial Infarction Early
emodeling) study failed to confirm them (59). In the
REMIER study, patients with LV ejection fraction40%
fter an ST-segment elevation myocardial infarction were
andomly assigned within 48 h after their infarction to
eceive either a broad MMP inhibitor (PG-116800) or
lacebo and were followed up for 90 days to evaluate the
ffects on LV volumes measured by echocardiography. No
ignificant benefit was found. This disappointing finding
ay be a result of better reperfusion and medical therapy
ith angiotensin-converting enzyme inhibition and beta-
lockade, or simply, as the researchers suggest, a too-small
ose of the inhibitor agent to elicit a clinically measurable
esponse.
Despite this failure, recent discoveries of oxidative/
itrosative activation and phosphorylation of MMPs, as well as
ovel non–matrix-related intracellular and extracellular targets
f MMPs, give hope for the development of newer MMP
nhibitors (60). In addition, a potential new mechanism of
MP inhibition through recombinant matricellular pro-
eins (i.e., nonstructural glycoproteins that regulate interac-
ions between cardiac cells and extracellular matrix) can be odvanced. In fact, it has been reported that increased levels
f the matricellular protein thrombospondin-2 reduce
MP-2 activity per se by scavenging of the MMP-
hrombospondin-2 complex through the lipoprotein-related
rotein receptor (61).
In summary, the therapeutic modulation of myocardial
ollagen matrix must be designed to restore the equilibrium
etween the synthesis and degradation of collagen to both
reserve the physiologic cardiac collagen matrix and prevent
r eliminate the pathologic accumulation of fibrotic tissue.
n addition, the strategies designed to reach this aim should
rovide cardiac-specific targeting to maintain tissue struc-
ure and preserve tissue repair in other organs.
ardiomyocyte Death
he loss of functional cardiomyocytes involved in the
rogression from cardiac injury to symptomatic HF can be
ttributable to various modalities of cell death, including
poptosis, necrosis, and autophagy, that are interconnected by
ommon cellular pathways at multiple points (62) (Fig. 4).
lthough the significance of the contribution of apoptotic cell
eath to myocardial remodeling continues to be debated,
ssociations of apoptosis with LV wall thinning and chamber
ilation, and deterioration of systolic performance have been
ound in experimental models and clinical studies (10).
hereas completely executed apoptosis leads to cardiomyo-
yte death and reduction of functioning cardiomyocyte
ass, the potential also exists for activation of upstream
poptotic steps only leading to compromise of adenosine
riphosphate production and diminished functional effi-
iency of viable cardiomyocytes (10) (Fig. 4). Therefore, the
otion has emerged that apoptosis inhibition is likely to be
necessary adjunct to cardiomyocyte regeneration in the
lobal strategy of “myocardial salvage” (62).
Whereas some studies have shown that direct caspase
nhibition reduces the acute loss of myocardium in various
nimal models, other studies indicate that caspase inhibition
ight not be able to completely inhibit apoptosis, likely
ecause apoptosis can be induced in the ischemic-hypoxic
njured heart lacking caspase activation by caspase-
ndependent pathways (63). Nevertheless, regarding alter-
ative potential antiapoptotic therapies indirectly related to
aspase inhibition for which some proof of principle exists,
t is worth considering that UCF-101 (a small-molecule
nhibitor of the mitochondrial Omi/HtrA2 serine protease
eleased into the cytoplasm during induction of apoptosis,
hat in turn promotes caspase activation) rescues cardiomyo-
ytes and restores LV dysfunction after ischemia/reperfusion
njury in the rat heart (64).
As in the case of fibrosis considered in the preceding text,
merging evidence has shown that microRNAs and factors
eleased from stem cells play a role in regulating apoptosis in
he heart, suggesting that they can be therapeutic targets for
poptosis-related cardiac diseases (65,66). For instance,
verexpression of miR-320 has been shown to enhance
1839JACC Vol. 58, No. 18, 2011 Gonza´lez et al.
October 25, 2011:1833–43 Myocardial Remodelingapoptosis in cardiomyocytes, whereas knockdown of miR-
320 or in vivo treatment with antagomir-320 can attenuate
apoptosis and reduce infarct size upon ischemia/reperfusion
(67). Additionally, some experimental data suggest that
factors released by stem cells in infarcted hearts (i.e., IL-10,
osteopontin, and clusterin) may reduce adverse remodeling
and enhance cardiac recovery (68,69).
Although a significant proportion of necrotic deaths are
passive, evidence has emerged that necrosis can also be
regulated and thus therapeutically interfered with (70). For
instance, cyclosporine A, which inhibits necrosis by block-
ing the mitochondrial permeability transition pore, has been
shown to reduce infarct size in the mouse (71). In a small
study of 58 patients with acute ST-segment elevation
myocardial infarction, cyclosporine A, administered imme-
diately before angioplasty/stenting, significantly reduced
creatine kinase release and infarct size by magnetic reso-
nance imaging during the first 5 days (72). Although this
pilot study suggests that cyclosporine A may reduce infarct
size in human ST-segment elevation myocardial infarction
Figure 4 Mechanisms and Potential Relationships Among Auto
AIF  apoptosis-inducing factor; Apaf  apoptosis protease-activating factor; Atg 
cyclophilin-D; Cyt c  cytochrome c; dATP  deoxyadenosine triphosphate; DNA 
permeable pore; MPTP  mitochondrial membrane transition pore; PUMA  p53 u
mitochondrial membrane potential.treated with reperfusion, the numbers are too small to drawany firm conclusions, and evaluation of cardiac function and
long-term follow-up are needed. Finally, necrostatin-1, also
an inhibitor of the mitochondrial membrane transition pore
and thus protector of the mitochondrial integrity and
function, is able to decrease infarct size in experimental
models of ischemia/reperfusion (73,74).
Several observations indicate that constitutive autophagy
in the heart under physiological conditions is a homeostatic
mechanism for maintaining cardiomyocyte size and global
cardiac structure function. The controversy arises when
considering the role of autophagy in myocardial infarction
because it has been described to be protective during
ischemia but detrimental during reperfusion (75). Similarly,
although failing human hearts exhibit an increased number
of autophagosomes, suggestive of increased autophagy
(76,77), further examination of the details of this process is
necessary to evaluate whether autophagy plays a protective
or a deleterious role in heart failure, thus making premature
any attempt to target it therapeutically.
Because cumulative evidence unquestionably points to the
y, Apoptotic, and Necrotic Pathways
phagy-related genes; ATP  adenosine triphosphate; Casp  caspase; Cyp-D 
ribonucleic acid; Endo-G  endonuclease-G; frag  fragmentation; Ipp  ion-
lated modulator of apoptosis; ROS  reactive oxygen species; m  innerphag
auto
deoxy
p-regumitochondria as arbiters of the different cardiomyocyte
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Myocardial Remodeling October 25, 2011:1833–43death pathways (Fig. 4), mitochondria-targeted interven-
tions aimed to the preservation of mitochondrial integrity
and function remain a focal point of ongoing research in the
therapeutic modulation of cell death. Currently, most efforts
along these lines focus on preventing the mitochondrial
oxidative damage that arises from ischemic or hypoxic
conditions (78). Additionally, a number of signal transduc-
tion studies have proven that mitochondrial integrity can be
enhanced by kinases involved in cell survival, in particular
Akt kinase or PKB (79). In this conceptual framework, the
connection between insulin-like growth factor (IGF)-I sig-
naling, Akt, and mitochondrial protection (80) points to
IGF-I as a potential therapeutic candidate. This is further
supported by the clinical observation that in studies of
patients with HF, IGF-I levels are low and correlate with
the severity of LV systolic dysfunction (81,82). However, no
studies have investigated yet the actions of direct IGF-I
supplementation in HF patients. Additionally, recent evi-
dence has been provided on a novel strategy to preserve
mitochondrial function and cardiomyocyte death by down-
regulation of the protein Nogo-A, which cardiac expression
is elevated in experimental models of dilated cardiomyopa-
thy and in humans with end-stage HF (83).
In summary, apoptosis, necrosis, and autophagy may
coexist in a variety of relationships (i.e., in parallel and in
series, with either up-stream of the other). Should this
scenario bear out, it would necessitate a careful investigation
of the contribution of each type of cell death to myocardial
remodeling. In addition, this possibility has potential ther-
apeutic implications, as drugs that inhibit one pathway may
shift death to another (e.g., caspase inhibitor shifting death
receptor-induced apoptosis to necrosis) (62).
Future Directions
Findings from recent experimental studies suggest that gene
therapy may have a place in myocardial remodeling. For
instance, cardiac-specific replenishment of local vascular
endothelial growth factor (84) or hypoxia-inducible factor
1- (85) restores microvascular homeostasis, repairs myo-
ardial remodeling, and improves LV function in rodents
ith diabetic cardiomyopathy independently of systemic
etabolic changes. Conversely, it has been recently reported
hat long-term cardiac pro–B-type natriuretic peptide gene
elivery prevents myocardial remodeling and improves LV
unction in rats with hypertensive heart disease, these effects
eing independent of blood pressure changes (86). How-
ver, researchers continue to investigate new genes and
ombinations of genes and approaches that combine gene
nd cell therapy, and to develop novel expression vectors and
elivery systems.
Small molecule histone deacetylase inhibitors block myo-
ardial remodeling in animal models, suggesting an unfore-
een potential for these classes of compounds for the
reatment of HF. Indeed, chronic treatment of spontane-
usly hypertensive rats with valproic acid (87) and deoxy-orticosterone acetate-salt hypertensive rats with suberoyla-
ilide hydroxamic acid (88) reduced myocardial expression
f IL-1 and TNF-, which correlated with suppression of
interstitial fibrosis and reduction of LV hypertrophy. Nev-
ertheless, several pre-clinical questions remain to be an-
swered before histone deacetylase inhibitors can move
toward clinical testing for treating HF.
A growing body of evidence supports the hypothesis that
autocrine and paracrine mechanisms, mediated by factors
released by the resident cardiac cells, could play an essential
role in cytoprotection, angiogenesis, and extracellular matrix
turnover in the remodeled myocardium (89). The recent
demonstration that chemically or genetically activated car-
diac cells may release molecules to protect tissue against
mechanical, ischemic, or metabolic injury provides a poten-
tial route to achieve the delivery of specific molecules
produced by these cells for innovative therapy of the
remodeled myocardium.
Recent evidence suggests that glucagon-like peptide-1
and the exenatide analogue AC 3174 exert antiremodeling
and cardioprotective effects in animal models of myocardial
infarction (90) or hypertensive heart disease (91), these
effects being independent of changes in systemic hemody-
namics and glucose metabolism. Hence, pharmacology of
glucagon-like peptide-1 (e.g., glucagon-like peptide-1 re-
ceptor agonists and dipeptidyl peptidase-4 inhibitors) may
represent a novel approach for the treatment of myocardial
remodeling in cardiac diseases associated with diabetes
mellitus or not.
Mechanical circulatory support provided by LV assist
devices and electromechanical synchronization provided by
cardiac resynchronization therapy have been shown to
regress myocardial remodeling (e.g., inflammation, fibrosis,
and apoptosis) and to improve LV geometry, contractile
function, and hemodynamic parameters in HF patients
(92,93). These promising findings should inspire further
research to better understand the mechanisms responsible
for both myocardial remodeling and its regression in this
particular setting.
Conclusions
In spite of a substantial improvement in outcomes in the
past 2 decades, we continue to face significant challenges in
treating patients with HF. Because conventional medical
strategies for the treatment of HF do not correct the
underlying cause (i.e., remodeling of the myocardial struc-
ture that reduces viable or functional myocardial tissue),
there is a necessity to focus on new strategies that target
mechanisms responsible for some of the cellular and tissue
lesions characteristic of the remodeled myocardium. We
realize that a large number of studies on these novel
strategies were not discussed in this brief review because our
only intention was to highlight a selected group of topics
that were more recently identified or that were consistent
with the theme at hand (Table 2). In addition, although
1
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myocardial remodeling have been gained through the use of
animal models, the physiological differences between the
cardiovascular systems of animals and humans, with respect
to myocardial remodeling and LV dysfunction, are an
important consideration. In particular, an important chal-
lenge in translating the observations from pre-clinical stud-
ies into clinical treatment strategies relates to clinical studies
being designed on top of established pharmacological ther-
apy, whereas most experimental studies test novel interven-
tions without concomitant drug regimens such as anti–
renin-angiotensin system drugs. In addition, because HF is
a complex, multifactorial syndrome consisting of many
overlapping phenotypes, the dynamic and heterogeneous
nature of myocardial remodeling cannot be captured by a
simplified pathophysiologic view, and as a consequence, its
therapy cannot be considered under a reductionist approach.
Nevertheless, data here reviewed provide essential informa-
tion for identifying potential novel targets, and their poten-
tial drawbacks, and are thus required for developing novel
treatment strategies to prevent or reverse myocardial remod-
eling that leads to LV dysfunction and HF.
Reprint requests and correspondence: Dr. Javier Dı´ez, Division
of Cardiovascular Sciences, Centre of Applied Medical Research,
University of Navarra, Av. Pı´o XII, Pamplona 55 31008, Spain.
Summary of Emerging Targets and Potential Therapeutic Agents toTable 2 Summary of Emerging Targets and Potential Therapeut
Alteration Target
Inflammation
TNF-
IL-1
PI3K/
IL-6 gp130/STAT3
TLR4
NF-B
Alterations of collagen matrix
Renin-angiotensin system
Aldosterone
TGF-1
PCP/PCPE
LOX
miR-21
MMPs
Several
Cardiomyocyte death
Mitochondrial Omi/HtrA2
Nogo-A protein
miR-320
Akt protein
ACEI angiotensin-converting enzyme inhibitor; Akt protein kinase B; ARB angiotensin recepto
30/signal transducer and activator of transcription 3; LOX  lysyl oxidase; MMP  matrix meta
rocollagen type I carboxy-terminal proteinase/PCP enhancer; PI3K/  phosphoinositide-3 kina
eceptor; TNF  tumor necrosis factor.E-mail: jadimar@unav.es.REFERENCES
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